Neurogene Inc. announced its first quarter 2025 financial results on May 9, 2025, reporting a net loss of $22.647 million for the quarter. This compares to a net loss of $16.921 million for the first quarter of 2024, indicating an increased burn rate.
On a per-share basis, the company reported a loss of $1.08, which did not meet the average analyst estimate of $1.05 per share. Research and development expenses for the quarter increased to $17.760 million from $13.541 million in the prior year period.
Neurogene reiterated its expectation to provide an update on its registrational trial plans for NGN-401 in the first half of 2025 and to share updated interim clinical data from the ongoing NGN-401 Phase 1/2 trial in the second half of 2025. The company also confirmed its cash runway into the second half of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.